Immatics (NASDAQ:IMTX) Shares Bought by Sphera Funds Management LTD.

Sphera Funds Management LTD. grew its stake in Immatics (NASDAQ:IMTX) by 27.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 921,111 shares of the company’s stock after purchasing an additional 200,000 shares during the quarter. Immatics makes up 1.2% of Sphera Funds Management LTD.’s holdings, making the stock its 28th biggest position. Sphera Funds Management LTD.’s holdings in Immatics were worth $6,549,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Paradigm Biocapital Advisors LP raised its position in shares of Immatics by 38.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company’s stock worth $38,496,000 after purchasing an additional 1,509,547 shares during the last quarter. Orbimed Advisors LLC raised its position in shares of Immatics by 53.9% during the 4th quarter. Orbimed Advisors LLC now owns 3,087,462 shares of the company’s stock worth $21,952,000 after purchasing an additional 1,081,081 shares during the last quarter. Millennium Management LLC raised its position in shares of Immatics by 379.2% during the 4th quarter. Millennium Management LLC now owns 156,686 shares of the company’s stock worth $1,114,000 after purchasing an additional 123,986 shares during the last quarter. Lazard Asset Management LLC raised its position in shares of Immatics by 186,686.2% during the 4th quarter. Lazard Asset Management LLC now owns 162,504 shares of the company’s stock worth $1,155,000 after purchasing an additional 162,417 shares during the last quarter. Finally, Graham Capital Management L.P. acquired a new position in shares of Immatics during the 4th quarter worth about $130,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Price Performance

Immatics stock opened at $4.69 on Friday. The firm has a 50 day simple moving average of $4.47 and a 200-day simple moving average of $5.90. Immatics has a 1-year low of $3.30 and a 1-year high of $13.77. The stock has a market cap of $570.07 million, a price-to-earnings ratio of -7.11 and a beta of 0.87.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The business had revenue of $20.12 million during the quarter, compared to analysts’ expectations of $14.92 million. Equities analysts expect that Immatics will post -0.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research report on Tuesday, April 1st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $16.67.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.